In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Keeping It Real: Communicating Authentically About Diversity, Equity And Inclusion

Executive Summary

In Vivo’s 2021 Rising Leader Alvine Tremoulet favored backroads over the corporate highway en route to her current position as global diversity, equity and inclusion lead at Pfizer. Tremoulet’s background in communications, and a strong network of female leaders, helped her to successfully influence internal and external stakeholders on issues still considered taboo in many parts of the world.

You may also be interested in...



Smart Investing: Picking Winners In Gene Therapy

Venture capitalists and industry executives discussed strategies for placing smart bets on emerging gene therapy companies during a recent virtual panel.

Successful Leadership In Uncertain Times

In conjunction with In Vivo’s Rising Leaders series, a panel of senior executives representing a wide spectrum of the life sciences industry – from large biopharmaceuticals to small biotech and cancer diagnostics – was convened to discuss what it takes to successfully lead during times of uncertainty and upheaval. Insights on communication strategies, navigating team integrations, supporting diversity and inclusion, and getting the most from multi-generational employees rested on a common theme: valuing people and anticipating workforce needs.        

Science 37 Blockbuster SPAC Valuation Points To Growth In Decentralized Trials

Expanding partnerships with CROs, the COVID-19 lockdown, an eager FDA and an industry desire for faster and more diverse clinical trial recruiting helped Science 37, a decentralized clinical trial company, nail down plans to go public. Science 37 CEO David Coman spoke with In Vivo about the reasons for going public via SPAC, and why decentralization is a “prerequisite to operating a clinical trial today.” 

Topics

Related Companies

UsernamePublicRestriction

Register

IV124786

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel